Affimed N.V. $34.5 Million Offering of Common Shares
Davis Polk advised the underwriters in connection with the $34.5 million public offering of 13,800,000 common shares of Affimed N.V. The offering included 1,800,000 common shares sold…
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
Agios Pharmaceuticals, Inc. Common Stock Offering
Davis Polk advised the joint book-running managers and representatives of the several underwriters in connection with the SEC-registered offering of 9,487,500 shares of common stock of…
Applied Therapeutics, Inc. Common Stock PIPE Offering
Davis Polk advised the placement agents in connection with a private placement of shares of common stock of Applied Therapeutics, Inc. The aggregate proceeds of the private placement…
Davis Polk Advises Centogene N.V. on Its Initial Public Offering
Davis Polk advised Centogene N.V. on its $56 million initial public offering of 4,000,000 of its common shares. In addition, Centogene has granted the underwriters a 30-day option to…
RAPT Therapeutics, Inc. Initial Public Offering
Davis Polk advised the underwriters in connection with a $38.4 million initial public offering of common stock of RAPT Therapeutics, Inc. RAPT Therapeutics’ common stock is listed on…
Progyny $149.5 Million Initial Public Offering and Nasdaq Listing
Davis Polk advised the underwriters on the SEC-registered initial public offering by Progyny, Inc. of 11,500,000 common shares, consisting of 6,700,000 shares sold by Progyny and 4,800,000…
Davis Polk Advises Charles River Laboratories International, Inc. on Its $500 Million Notes Offering
Davis Polk advised Charles River Laboratories International, Inc. in connection with its Rule 144A/Regulation S offering of $500 million aggregate principal amount of 4.250% senior notes…
Innate Pharma $79 Million U.S. Initial Public Offering of ADS on Nasdaq and Concurrent Private Placement
Davis Polk advised the underwriters in connection with an initial public offering of 8,047,227 American Depositary Shares of Innate Pharma S.A. and a concurrent private placement of 4,452…
Natera, Inc. $230 Million Follow-On Public Offering
Davis Polk advised the several underwriters in connection with the follow-on offering of 6,571,428 shares of common stock of Natera, Inc. for total gross proceeds of approximately $230…
BioNTech SE Initial Public Offering on Nasdaq
Davis Polk advised the underwriters in connection with the $150 million initial public offering of 10,000,000 American Depositary Shares of BioNTech SE. In addition, the underwriters have…